Shares of hVIVO plc (LON:HVO – Get Free Report) were down 6.8% during trading on Thursday . The company traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). Approximately 2,518,262 shares were traded during trading, a decline of 26% from the average daily volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.25).
hVIVO Stock Down 6.8 %
The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The stock’s 50-day moving average price is GBX 23.58 and its two-hundred day moving average price is GBX 26.77. The stock has a market capitalization of £129.95 million, a PE ratio of 636.67 and a beta of 0.97.
About hVIVO
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Read More
- Five stocks we like better than hVIVO
- Compound Interest and Why It Matters When Investing
- 3 Legacy Tech Companies Reemerging as AI Leaders
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- Which Wall Street Analysts are the Most Accurate?
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
